Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
US-2026091033-A1 · Apr 2, 2026 · US
Imagine holds 9 patents in our database, with recent filings and technology areas summarized below.
| Metric | Value |
|---|---|
| Total patents | 9 |
| Recent patents | 2 |
| First publication | Feb 25, 2016 |
| Latest publication | Apr 2, 2026 |
Year-over-year patent counts for this assignee.
Latest publications where this party is an assignee.
US-2026091033-A1 · Apr 2, 2026 · US
US-2024350490-A1 · Oct 24, 2024 · US
US-2023075776-A1 · Mar 9, 2023 · US
US-11357778-B2 · Jun 14, 2022 · US
US-2022031696-A9 · Feb 3, 2022 · US
Representative or frequently cited publications from precomputed assignee stats.
US-2026091033-A1 · Apr 2, 2026 · US
US-2024350490-A1 · Oct 24, 2024 · US
US-2023075776-A1 · Mar 9, 2023 · US
US-11357778-B2 · Jun 14, 2022 · US
US-2022031696-A9 · Feb 3, 2022 · US
Mapped technology topics for this assignee.
| Technology | Patents |
|---|---|
| Human Necessities | 9 |
| Operations & Transport | 9 |
| Chemistry & Metallurgy | 9 |
Answers are generated from the same data shown on this page.